2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Conditions
Glioblastoma
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Brain Neoplasms
3
Virus Diseases
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Melanoma
2
Liver Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Interventions
Valproic Acid
2
Temozolomide
2
Oncolytic Virotherapy
2
Magnetic Resonance Spectroscopy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vorasidenib
1
trametinib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
palbociclib
1
mirdametinib
1
interferon gamma-1b
1
imetelstat
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
fludarabine
1
Verteporfin
1
Thiotepa
1
Tacrolimus
1
Radiotherapy
1
ONC206
1
Mycophenolic Acid
1
Melphalan
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Immunologic Techniques
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Neuroepithelial
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled